Daniel Tomaszewsi, Pharm.D., Ph.D., is an Assistant Professor in Pharmacy Administration in the Biomedical and Pharmaceutical Sciences Department. Dr. Tomaszewski completed his Pharm.D. and Ph.D. at the University of Minnesota, College of Pharmacy. While working towards his Ph.D., Dr. Tomaszewski has had a wide variety of teaching, practice, and research experiences. He has provided Medication Therapy Management, served as the primary pharmacy preceptors for local and international student run health clinics, worked as a pharmacist in community pharmacies, and has worked for a pharmacy benefit manager.
In 2014, Dr. Tomaszewski joined the faculty at the University of Minnesota, College of Pharmacy as an Assistant Professor in the fall of 2012. In the fall of 2014, Dr. Tomaszewski joined the Chapman University School of Pharmacy as an Assistant Professor. Throughout his time in academia, Dr. Tomaszewski has taught coursework in the Doctor of Pharmacy Program, Masters Program, and Doctorate of Philosophy Program.
Dr. Tomaszewski has focused his research in three primary areas, use of opioids in pediatric patients, medication adherence, and drug pricing/policy. With regard to pediatric opioid use, Dr. Tomaszewski’s research program evaluates the use of opioid in a variety of healthcare settings. These include evaluating prescribing patterns and use of opioids in inpatient care facilities, emergency departments, and ambulatory clinic visits. Current projects are focused on a dual approach of conducting retrospective analysis of opioid use patterns and factors impacting these prescribing patterns, while developing prospective analysis and intervention development to optimize opioid prescribing and use. As for medication adherence research, Dr. Tomaszewski has focused on retrospective analysis and cross-sectional survey research to evaluate modifiable factors to improve adherence and persistence in the use of chronic prescription medications. Drug pricing/policy research has focused primarily on evaluating healthcare provider perceptions of biosimilars and the economic impact biosimilars have had on FDA approved biopharmaceuticals.
KEYWORDS: Pediatric opioid use, opioid use/misuse, medication adherence, medication